University of North Carolina at Chapel Hill
An internist and clinical epidemiologist, over the past 25 years Dr. Baron has had leading roles in the conceptualization, conduct, and interpretation of numerous clinical trials and epidemiological studies. Many of these have addressed issues in the epidemiology and prevention of cancer. As a member of the Steering Committee of the Colon Cancer Family Registry, he has helped develop one of the largest cohorts of colorectal cancer cases in the world. Dr. Baron has also been active in the Early Detection Research Network, where he serves as the clinical epidemiologist for a validation center investigating gastrointestinal early detection markers.
He leads the Polyp Prevention Study Group, which has conducted several important adenoma prevention clinical trials that have been instrumental in clarifying the effects of antioxidants, calcium, aspirin, and folic acid on these common neoplasms. Dr. Baron has also served on the Safety and Data Monitoring Boards of several prominent trials, including SELECT and the recent DFMO/sulindac trial recently reported by Meyskens et al.